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POSITRON EMISSION TOMOGRAPHY (PET)
has enabled the neuroscientist to visualize and to quantitate, in transverse section, the distribution of radiopharmaceuticals of biological interest within the living human brain. 1 "* An important but, as yet, incompletely investigated application of PET technology is the quantitative mapping of regional cerebral blood flow (rCBF) in patients with neurological diseases and in normal subjects during functional activation. An interest of our laboratory is the development of a rigorous "in vivo autoradiographic" paradigm for determining rCBF, analogous to the autoradiographic technique for rCBF which has been widely employed in experimental animals (for recent review, see reference 4). The latter method has been applied to the study of blood flow heterogeneities in the normal brain;'"' the relationship of rCBF to local brain metabolism;" and the investigation of rCBF changes produced by physiological alterations 10 and by disease states such as cerebral ischemia. Iodoantipyrine (IAP) labelled with carbon-14 has recently been demonstrated by Sakurada and coworkers' to be a highly suitable tracer for autoradiographic rCBF measurements in experimental animals. IAP is a non-polar, metabolically inert, highly diffusible compound of low molecular weight. It has a high lipid solvent:water partition coefficient and a braimblood equilibrium partition coefficient that is uniform throughout the brain.' It is significantly less diffusion-limited and hence more accurate in measuring higher rates of rCBF than antipyrine, which was formerly used for rCBF autoradiography. ' In the present study, iodoantipyrine labelled with the positron-emitting radionuclide carbon-11 has been synthesized and we have validated the suitability of this product for the measurement of rCBF in the rat as a prelude to its possible application as a blood flow tracer in human studies using emission tomography. Preliminary findings have been reported in abstract form."
Materials and Methods
Synthesis of "C-Iodoantipyrine Carbon-11 (T H = 20.4 min) was prepared in a CS-30 cyclotron (Cyclotron Corp.) by the M N(p,a) n C nuclear reaction. "No-carrier-added" "COt was synthesized by the method of Finn and Wolf," and ••C-methyl iodide was prepared from it by reduction with lithium aluminum hydride and distillation of the labelled methanol through hydriodic acid. This, in turn, was reacted with 3-methyl-l-phenyl-2-pyrazolin- 5-one to produce "C-antipyrine plus other, undesired, methylated products which were removed on a silica gel column. n C-iodoantipyrine was then prepared by iodination of n C-antipyrine and was separated from the latter and from inorganic iodine residues on a silica gel column. The product was sterilized by Millipore filtration. Analyses by means of thin-layer chromatography and high performance liquid chromatography confirmed the product to be n Ciodoantipyrine with a radiochemical purity of 93-98%, except in the special instances to be described below. Specific activity was approximately 30 Ci/mmole. Campbell and co-workers have presented a complete account of this synthesis. 1 
' Animal Preparation
Wistar rats weighing 300-400 gm were anesthetized with diethyl ether, tracheostomized, immobilized with d-tubocurarine (1.8 mg i.p.), and ventilated mechanically on mixtures of 70% nitrous oxide and 30% oxygen. Catheters were inserted into one external jugular vein and one or both femoral arteries. Mean arterial blood pressure was recorded by a transducer (Statham) and displayed on an analog meter (Stentor). Arterial blood gases were monitored periodically with a multi-electrode analyzer system (Corning). Rectal temperature was maintained at 37°C by a thermostatically controlled heating lamp.
Regional Cerebral Blood Flow (rCBF) rCBF was measured by the method of indicator fractionation." In these studies, we wished to compare rCBF as measured by U C-IAP synthesized in our laboratory with rCBF measured using commercially prepared "C-IAP (4-[N-methyll4 C] -iodoantipyrine, New England Nuclear, specific activity 40-60 mCi/mmole). Thus, a mixture of 100-500 jtCi of ll C-IAP and 30 (id of "C-IAP dissolved in 300 n\ normal saline was injected as a bolus into the external jugular vein via a short catheter. An infusion/withdrawal pump (Harvard Apparatus Co.) was used to withdraw an arterial "reference organ" blood sample at a precalibrated, constant rate (approximately 0.15 ml/min) into a 50 cm-long P.E. 50 polyethylene catheter via a 250 jtl microliter syringe (Hamilton). The withdrawal of arterial blood was begun just prior to tracer injection. Seven sec after injection, the animal was decapitated, and the "reference organ" arterial catheter was simultaneously extracted from the animal and its contents delivered into a vial containing 500 n\ isopropanol-Soluene-350 (Packard) (1:1, v:v), to which 200 fil hydrogen peroxide was added. The brain was removed and dissected into the two cerebral hemispheres, cerebellum, and brainstem. Each cerebral hemisphere was bisected into anterior and posterior quadrants. All brain samples were weighed. A sodium iodide well counter was used to measure n C activity of the "reference organ" blood sample and brain samples; this instrument detected the 511 keV emission of "C but was insensitive to the 0-emission of "C. The n C count rates were corrected for background activity and for U C decay. Measurement of "C activity was delayed by at least one day to permit complete decay of "C. C data sets. To examine this further, a ("C-CBF/'KNCBF) ratio was computed for each analyzed brain sample from each animal, and a mean ratio was calculated for each ani- mal. These values are shown in table 2. The series mean for this ratio is 0.96, and its 95% confidence limits are 0.88-1.04. Thus, the tendency for n C-IAP to underestimate rCBF relative to "C-IAP does not attain statistical significance. rCBF values were highly correlated with arterial Pcoi. Figure 3 shows this relationship for mean cerebral hemispheral CBF as measured with "C-IAP in the 9 animals of this series. If one assumes a linear relationship between arterial Pco, and rCBF within the range studied, these data indicate a CBF responsiveness of 0.048 ml gnr 1 18 and in other species." This discrepancy may be due in part to the limited number of data points in our series, particularly in the mid-range of Pco, (fig. 3) . Figure 4 emphasizes the importance of performing quality control on each batch of ll C-IAP prior to its use in measuring rCBF. In a study in which thin-layer chromatography of the u C-product revealed no IAP to be present, the apparent "rCBP' as measured with this product was markedly reduced compared with values obtained with "C-IAP ( fig. 4A) . In another study, the n C-product had been heated to enhance its solubilization; this resulted in heat-decomposition of the product. rCBF values obtained with the u C-product were consistently below those obtained with '•C-antipyrine, which, by virtue of its greater diffusion-limitation, tends to underestimate rCBF of graymatter structures relative to iodoantipyrine.*
Discussion
The data of this study demonstrate that 1X Ciodoantipyrine, when synthesized as described and 
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subjected to proper quality control, can be used for accurately measuring rCBF in the experimental animal and thus would be expected to be suitable for the emission-tomographic measurement of rCBF in man. Certain qualifications, however, must be appended. As the data of figure 4 suggest, batch-by-batch quality control of the "C-product is essential if valid rCBF results are to be assured. Antipyrine, the immediate precursor of n C-IAP, has been shown by several workers to be significantly permeability-limited at normal rates of gray-matter blood flow and to produce a falsely low estimate of rCBF. 8 ' ao~" The percentage by which antipyrine underestimates rCBF relative to IAP is calculated from the data provided by Sakurada et al. to average 39% for gray-matter structures of the conscious rat. 8 In the study shown in figure 4B , the 23% decrement observed approximates this value and suggests that the n C-product in that instance may have consisted in part of antipyrine or a related, permeability-limited u C-labelled substance. Apart from the necessity for proper quality control, an additional disadvantage of "C-IAP is the relative difficulty of scaling its synthesis up to the 5-10 mCi amount required for human emission-tomographic imaging. In this respect, 10 O-labelled water (T w 123 sec), which we are also investigating, appears to be a superior tracer for human rCBF studies inasmuch as it can by synthesized readily with high purity and ample yield (typically, 50 mCi in a volume of 50 n\) by a simple and straightforward strategy."
For tomographic studies of rCBF in man employing an autoradiographic paradigm, an estimated dose of 5-10 mCi of n C-IAP would be required, to be administered by intravenous infusion over 1-2 min. The resulting radiation exposure to the patient is determined by the physical half-life of the radionuclide and the biodistribution of the radiopharmaceutical. IAP has been shown to approach equilibrium in the blood within 10 min of its intravenous administration and to have a calculated distribution volume approximating 65% of body weight." Significant amounts of inorganic iodide detach from the IAP molecule within 15 min, and up to 70% of this iodide appears in the urine within 24 h."-" The resulting "C-antipyrine has a biologic half-life of 7 to 20 h in plasma and is distributed throughout body water. 26 Thirty to 40% of the antipyrine is oxidized to 4-hydroxyantipyrine, rapidly conjugated to the glucuronide and possibly sulfate, and excreted. The metabolic fate of the remainder is not known. The physical half-life of n C (20.4 min) is considerably shorter than the biological half-life of either IAP or its metabolite, antipyrine, and is thus the chief determinant of the radiation dose to the patient. If one assumes a uniform whole body distribution and 100% retention of the tracer, an injected dose of 10 mCi in a 70 kg man would result in an absorbed dose of 112 mRad to the whole body." This is an acceptable level to permit its use for rCBF studies in man.
We have recently developed and validated an "in vivo autoradiographic" strategy for measuring regional cerebral blood flow by positron emission tomography." In this method, blood flow is computed from the time-integrated cerebral activity curve resulting from a modified ramp intravenous infusion of a positron-emitting blood flow tracer such as 15 O-water or "C-iodoantipyrine administered over an interval of one min or more. This method holds promise for the measurement of rCBF in man by positron emission tomography. -" An accurate differentiation between stenosis and occlusion of the carotid arteries is impossible and the exact site of obstruction cannot be localized.
Incidence of Asymptomatic Extracranial
The more sophisticated application of the Continuous Wave (CW)-Doppler technique for direct insonation of the carotid arteries in the neck has considerably improved the value and reliability of the non-invasive examination, particularly for the carotid artery system. * allowing the additional detection of lesions producing obstructions of even less than 50% due to atherosclerotic changes in the normal laminar flow within the vessels.
14 With the new combination of real-time Bscan imaging and Doppler systems 15 
"
17 it may become possible to achieve a degree of resolution sufficient for the detection of even small ulcerated lesions of the arterial wall.
It has been reported that use of the Doppler technique to detect flow abnormalities in the vertebral arteries (flow reduction or steal phenomena) provides information on the adequacy of the posterior brain circulation. 
